Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhongnan Hospital
About this trial
This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.
Eligibility criteria
Qualifiers
18 years of age or older, of any nationality.
Patients diagnosed with malignant tumor.
Eligible patients will report altered sensations and/or pain and/or other neurological symptoms, with a grade between 2-3 for chemotherapy-induced peripheral neuropathy on the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events-version 5.0 (NCI-CTCAE.v-5.0).
Predicted life expectancy of ≥3 months.
Disqualifiers
History of pre-existing peripheral neuropathy before chemotherapy, including alcoholism, vitamin B deficiency, diabetes, HIV, congenital neuropathy, and toxic neuropathy.
Patients with skin damage, pus or scar at the acupuncture stimulation area.
Patients who are pregnant or breastfeeding.
Significant mental conditions.
Trial design
Treatments tested in this trial
- True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment
- Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov